Pyridino2,3-dpyrimidine derivatives as selective kdr and fgfr inhibitors
CA 2508951 A1 · Owner: F. Hoffmann-La Roche Ag · Inventors: Luk, Kin-Chun; Liu, Jin-Jun
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
Disclosed are novel dihydropridinone compounds of the formula (I) wherein Ar Ar' and R1 are as defined in the description that are selective inhibitors of , both KDR and FGFR kinases. These compounds and their pharmaceutically acceptable salts are anti-proliferative agents useful in the treatment or control of solid tumors, in particular breast colon lung and prostate tumors. , Also disclosed are pharmaceutical compositions containing these compounds and their preparation.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed December 11, 2003. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended December 11, 2023.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by December 11, 2025.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.